EnsiliTech

Our novel ensilication technology exploits the growth of protective silica nanoshells on the surface of vaccine components, to prevent degradation, which can lead to vaccine spoilage. Once applied, our vaccines can be stored and transported without the need for cold chain infrastructure, preventing wastage, improving shelf-life and increasing vaccine accessibility globally. Ensilication can be applied to protect a wide variety of biomolecules against environmental degradation, eliminating the need for cold chain requirements and propelling the development of more oral and mucosal delivery of vaccines and therapeutics for both animals and humans. We are actively looking for partners to work with...

Biotech,vaccines,antibodies,genetic material,thermal stability,and biologics

Ensilitech operates in the Biotechnology research industry.

Ensilitech's revenue is 11m - 100m

Ensilitech has 11 - 50 employees.